Keudell Morrison Wealth Management Buys 210 Shares of Merck & Co., Inc. (NYSE:MRK)

Keudell Morrison Wealth Management increased its stake in Merck & Co., Inc. (NYSE:MRK) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,714 shares of the company’s stock after purchasing an additional 210 shares during the quarter. Keudell Morrison Wealth Management’s holdings in Merck & Co., Inc. were worth $1,444,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Itau Unibanco Holding S.A. bought a new stake in Merck & Co., Inc. during the 2nd quarter valued at $39,000. Abich Financial Wealth Management LLC boosted its position in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the period. Quarry LP purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $42,000. Strategic Financial Concepts LLC raised its stake in shares of Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after acquiring an additional 32,832 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Merck & Co., Inc. by 47.5% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after acquiring an additional 122 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Morgan Stanley decreased their price target on shares of Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating for the company in a research note on Friday, November 1st. Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. UBS Group cut their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Guggenheim cut their price target on shares of Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Wells Fargo & Company cut their price target on shares of Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $129.80.

Merck & Co., Inc. Stock Up 0.4 %

Shares of NYSE MRK traded up $0.40 during trading hours on Thursday, hitting $101.13. 805,292 shares of the stock were exchanged, compared to its average volume of 8,818,050. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The company has a market cap of $256.14 billion, a PE ratio of 21.24, a PEG ratio of 1.46 and a beta of 0.40. The firm has a fifty day moving average price of $111.37 and a 200-day moving average price of $120.33. Merck & Co., Inc. has a 12 month low of $98.60 and a 12 month high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. The firm had revenue of $16.66 billion during the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 37.32%. Merck & Co., Inc.’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.13 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 7.76 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.